As GenomeWeb News reported, BioSource received a notice from the exchange in May indicating that the company was not in compliance with its requirements for continued listing because it failed to file a first-quarter financial report in a timely manner.
The company said at the time that the notice indicated its stock would be delisted if a financial report were not filed by July 3. BioSource filed its first-quarter return on June 28 and has received notification from the Nasdaq Office of General Counsel, Listing Qualifications Hearings "confirming compliance with SEC filing requirements and all other requirements for continued listing on the Nasdaq National Market."
The stock had been trading under the amended symbol "BIOIE" since May 27 after BioSource received the delisting notice.